Status:
ACTIVE_NOT_RECRUITING
Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies.
Lead Sponsor:
University of Leicester
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The NHS' Genomic Medicine Service offers whole genome sequencing as part of the drive to improve cancer outcomes. It is recognised that actionable mutations (current and emerging), will ultimately imp...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Diagnosed with solid tumour that requires surgical resection, and has a high propensity of relapse.
- Fit for planned surgical procedure.
- Able (in the Investigators opinion) and willing to comply with all study requirements.
- Willing to allow his or her General Practitioner, Consultant, and Clinical Geneticist, if appropriate, to be notified of participation in the study.
Exclusion
- Female participants who are pregnant, lactating or planning pregnancy during the course of the study.
- Not fit for surgery.
- Not willing to donate blood and tissue samples.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Participants who have participated in another research study involving an investigational product in the past 12 weeks.
Key Trial Info
Start Date :
February 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04853420
Start Date
February 16 2021
End Date
April 30 2026
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Leicester
Leicester, United Kingdom